Rubicon Research Limited share price
NSE: RUBICON · ISIN INE506V01022
Key numbers
- Market cap
- ₹ 27,748 Cr
- Current price
- ₹ 1,676.30
- 52-week high / low
- ₹ 1,899 / 571
- Stock P/E
- 96.2
- Book value
- ₹ 78.1
- Dividend yield
- 0.09%
- ROCE
- 22.0%
- ROE
- 19.1%
- Debt to equity
- 0.24
- Sales growth (3 yrs)
- -
- Profit growth (3 yrs)
- -
- 1-year return
- -
About Rubicon Research Limited
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. The company develops products in the areas of analgesics/pain management, cardiovascular system, central nervous system, hypokalemia, skeletal muscle relaxants, nicotine replacement therapy, gastrointestinal, metabolic, and immunosuppressant. Its primary proprietary technologies for drug delivery comprising RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption, as well as RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies. The company was incorporated in 1999 and is headquartered in Mumbai, India.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 358 | 352 | 476 | 514 | 534 |
| Operating profit | 72 | 70 | 108 | 119 | 129 |
| Net profit | 36 | - | 73 | 77 | 85 |
| EPS (₹) | 2.20 | - | 4.46 | 4.66 | 5.13 |
Concall summary (2026-08-19)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- But despite all these cost impact, we are slightly up guiding for around now earlier our guidance was 22% to 23% on EBITDA but now we are comfortable to revise this upwards for the whole of FY27 Rubicon Research Limited August 14, 2026 to 23%.
- And as you can see, our current R&D productivity based on this Q1 FY27 is about 5.5x.
Growth & demand
- So if you just from a percentage growth, year-on-year revenue has grown by 51%, EBITDA has grown by 65%, and PAT has grown by more than 95%.
- So our revenue from operation for the quarter was INR5,343 million, a growth of 52% versus the same quarter last year.
Margins & costs
- Our pre-R&D EBITDA was at INR 1,871 million, translating into 35% pre -R&D EBITDA margin versus 32.5% for the Q1 previous year.
- Coming to EBITDA, the operating EBITDA rose to 24.2% compared to 23.1% in the sequential quarter, which is again despite sharp increase in our input and freight cost due to the prevailing geopolitical conditions plus employee appraisals which have been concluded in Q1.
Capex & expansion
- This is the first quarter we are reporting since Arinna acquisition.
- The Arinna acquisition got closed in the month of April and the revenue impact is roughly around INR12 crores.
Balance sheet & cash
- Our operating cash flow before working capital change for the quarter was INR1,390 million.
- Our cash flow from net cash flow from operating activity was INR285 million.
Peers in Drug Manufacturers - General
Data for information only, not investment advice. Prices end of day.